Why anyone looked at carnitine and fatty liver
Non-alcoholic fatty liver disease means triglyceride piling up inside liver cells. Carnitine is
required to move long-chain fatty acids into mitochondria to be burned. If that step is sluggish, fat
accumulates. The mechanistic story is coherent, which is what prompted the trials.
This page summarises published research. It describes what studies have reported. It is not a claim about any product sold by Injectify, and it is not guidance for use in humans.
The pooled numbers
A systematic review and meta-analysis by Thiagarajan and colleagues pulled together five
randomised trials covering 338 people. Results, with the caveats immediately after:
- ALT, a liver enzyme, fell by a weighted mean difference of 25.34 IU/L against control
(p = 0.002). - AST, the other commonly measured enzyme, fell by 13.68 IU/L, and that did not
reach statistical significance (p = 0.066). - HOMA-IR, a measure of insulin resistance, improved by 0.74 units (p < 0.001).
- Two trials using validated measures reported less liver fat.
The AST result is the one to notice. If carnitine were producing a large, uniform effect on liver
injury, you would expect both enzymes to move together and clearly. One did and one did not.
Four reasons to hold this loosely
Five trials and 338 participants is a small evidence base. One study behaving unusually can shift
a pooled estimate noticeably at that size.
Liver enzymes are a convenient proxy, not the disease. Improving ALT is not the same result as
improving steatosis or fibrosis on a biopsy, and the endpoints that matter clinically are the harder
ones to measure.
Several trials ran alongside diet or lifestyle changes. Those work in fatty liver on their own,
which makes the carnitine contribution difficult to isolate.
Dose, duration, route, and population all varied between trials. That is exactly the situation
where a single pooled number is least informative, and it is why the confidence intervals deserve
more attention than the point estimates.
Where this leaves things
Suggestive and mechanistically sensible, not settled. Reviews in this area tend to close by asking
for larger trials with histological endpoints, which is a fair signal of how mature the evidence is.
Anyone designing work here should read the primary trials rather than a summary like this one.
References
- Thiagarajan P, Chalmers J, Ban L, Grindlay D, Aithal GP. L-carnitine supplementation in non-alcoholic fatty liver disease: a systematic review and meta-analysis. World J Meta-Anal. 2020;8(1):4-14. Full text
- Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004;1033:30-41. PMID 15591001
Research use only. Products discussed on this page are supplied for laboratory research. They are not medicines, not dietary supplements, and not for human or veterinary consumption. Nothing here is medical advice.